GlassScriptPhysician profile
Amy L Leezer
NPI 1487190641
$3,096.49
in general payments reported to CMS, 2019-2025
24 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $791 · 2023: $1,030 · 2024: $646 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $424.17 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $375.60 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $340.29 | 2022-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $290.40 | 2021-2024 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $271.99 | 2021-2024 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $257.14 | 2023 | |
| Abbott Laboratories | $241.01 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.00 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $170.99 | 2022-2025 | |
| Amgen INC. | $91.76 | 2022-2024 | Repatha |
| Pfizer INC. | $79.17 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $43.10 | 2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $40.22 | 2025 | Evkeeza |
| Esperion Therapeutics, INC. | $38.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.93 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $32.27 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $28.58 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $24.58 | 2021-2023 | Arcalyst |
| Abiomed | $22.66 | 2025 | |
| Novo Nordisk INC | $22.44 | 2025 | Ozempic |
| Boston Scientific Corporation | $20.66 | 2024 | Watchman Access System |
| Chiesi USA, INC. | $13.11 | 2021 | |
| Philips North America LLC | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Leezer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.